Overview
Antlia Bioscience Europe is developing novel long-acting therapeutics that target chronic cardiometabolic diseases.
Financials
Revenue history
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2023-03-24. Active
15 1050 1344 1000 0090 3293 2866
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the board of directors consists of two or more persons, joint action by two directors or by one director together with a commercial proxy is required to make declarations on behalf of the company. If the board of directors consists of one person, the sole director is entitled to represent the company independently.
Beneficial owners
| Person | Rights | |
|---|---|---|
Andrzej Olgierd Szczepanek (57)  | Shareholder of a simple joint-stock company, 100.0% | |
Tomasz Rafał Żurawski (49) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
FAQ
Last updated: 2026-07-16